Science Hub
Welcome to Novo Nordisk Science Hub
The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Professor Emmanuel Tsochatzis (MD, MSc, FEBTM, FRCP, PhD) is a Professor of Hepatology and Consultant Hepatologist at the UCL Institute for Liver and Digestive Health, Royal Free Hospital in London. He is Head of the Centre for Metabolic Liver Disease in ILDH and a member of the Baveno steering committee for portal hypertension. His main research interests include non-alcoholic fatty liver disease, cirrhosis and portal hypertension and non-invasive assessment of liver fibrosis.
Professor Tsochatzis finished his specialty training and PhD in Hippokration General Hospital in Greece, before moving to the Royal Free Hospital for his post-doc research under Professor Andy Burroughs. He is the recipient of the Rising Star in Gastroenterology prize by the UEG and the EASL Physician Scientist Fellowship.
His work on the cost-effectiveness of non-invasive fibrosis tests has informed the World Health Organization (WHO) guidelines on diagnosis and treatment of both HBV and HCV. He has designed and implemented a primary care pathway for NAFLD referrals to secondary care. He leads the specialist multidisciplinary service in NAFLD at the Royal Free Hospital and has an active research program in NAFLD. He has published more than 260 articles in peer-reviewed journals. He served a member of the EASL Governing Board from 2019 to 2022 and was the chair of the EASL Scientific Committee in 2021-22. He has received funding for his research from NIHR, EASL and EU Horizon 2020.
Dr Onno Holleboom MD, PhD
Internist-endocrinologist, assistant professor Amsterdam University Medical Center, Amsterdam, Netherlands
Dr. A.G. (Onno) Holleboom MD PhD is an internist registered in Vascular Medicine and Endocrinology, assistant professor at the Department of Vascular Medicine and Principal Investigator at Amsterdam UMC. He has a multidisciplinary clinic for patients with NAFLD together with hepatology including clinical trials. Within the NAFLD-NL consortium and supported by the MLDS foundation, he is developing care paths for NAFLD together with Leiden UMC and Radboud MC Nijmegen. Together with prof. Max Nieuwdorp, he runs a research group with 6 PhD candidates focussing on genetic and gut microbial drivers of NAFLD in three cohort studies, as well as more fundamental work on lipid droplet and inflammatory pathways. He has published 64 peer-reviewed articles, including in Circulation and Cell Metabolism and received various prestigious grants, a.o. from The Netherlands Organization for Scientific Research and the Amsterdam UMC Fellowship.
Read full bio
Prof Jörn M. Schattenberg
University Medical Center , Mainz, Germany
Jörn M. Schattenberg is a Professor of Medicine and Director of the Metabolic Liver Research Program at the University Medical Center Mainz, Germany. He received his medical degree in 2002 after studying at the University of Mainz (Germany) and at the Tulane University in New Orleans (US). He completed his post-doctoral training at the Albert-Einstein College of Medicine, New York, where he focused on delineating signaling pathways involved in the pathophysiology of acute and chronic liver injury with a special focus on metabolic liver disease and non-alcoholic steatohepatitis (NASH).
He is board-certified in Internal Medicine and Gastroenterology & Hepatology and Infectious Disease. He built up the Metabolic Liver Research Program that focuses on translational sciences and clinical trials. Additionally, he heads a liver research laboratory focusing on clinical and experimental aspects of liver injury, the development of therapeutic intervention and novel biomarkers in liver disease.
Professor Schattenberg is member of the Scientific Committee of the United European Gastroenterology (UEG), member of the Policy and Public Health Committee of the European Association for the Study of the Liver (EASL) and a member of the Editorial Board of Hepatology and the Alimentary Pharmacology & Therapeutics.
Read full bio